Skip to Content

Resmed (RMD)

RMD $34.96

20 minute delayed

trade now
Today ▲ 1.42%
1 year return ▼ -9.41%
Volume 744,127
Div yield 1.06%
PE ratio 21.66
52 week range
25.50 39.94

14 days free access

Join Market Matters and get full access to all our Opinion + Action

Learn more

Performance

Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
ASX:RMD chart by TradingView

Share price activity

Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
Last (Price)
34.96
Change
▲ 0.49 (1.42)
Bid / Ask
34.95 - 35.00
Volume
744,127
Turnover
26,044,486
Open
34.85
Day Range
34.81 - 35.14
VWAP
35.00
Prev Close
34.47
Last Trade
13/11 4:10pm
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
Ratios
Currency (Price/reporting): AUD/USD
Exchange Rate: 1.4738
Price, volume and trading statistics for the security, sourced from Morningstar.
Price - closing or last bid 34.47
Price - 12 month high 39.94
Price - 12 month low 25.50
Pricing date 11 NOV 2026
Volume - avg. trading volume for the last ten days 2.36
Market capitalization 48,484.49
12 Month High price date 26 NOV 2025
12 Month Low price date 3 JUN 2026
Volume - avg. trading volume for the last 3 months 1.53
Price - 1 Day % Change 1.77%
Price - 13 week price percent change 10.37%
Price - 26 week price percent change 20.44%
Price - 5 Day % Change 3.11%
Price - 52 week price percent change -10.12%
Price - YTD price percent change -4.09%
Price % Change Month To Date 5.80%
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
EPS excluding extraordinary items - most recent fiscal year 1.043
EPS excluding extraordinary items - trailing 12 month 1.098
EPS Normalized - most recent fiscal year 1.117
Revenue/share - most recent fiscal year 3.871
Revenue/share - trailing 12 month 3.949
Book value per share - most recent fiscal year 4.566
Book value per share - most recent half-year 4.229
Book value (tangible) per share - most recent fiscal year 2.235
Book value (tangible) per share - most recent half-year 1.846
Cash per share - most recent fiscal year 1.019
Cash per share - most recent half-year 0.719
Cash Flow per share - most recent fiscal year 1.287
Cash Flow per share - trailing 12 month 1.298
Dividend per share - most recent fiscal year 0.240
Dividends per share - trailing 12 month 0.361
EBITD per share - trailing 12 month 1.510
EPS Basic excluding extraordinary items - most recent fiscal year 1.047
EPS Basic excluding extraordinary items - trailing 12 month 1.101
EPS including extraordinary items - most recent fiscal year 1.047
EPS including extraordinary items - trailing 12 month 1.101
Free Cash Flow per share - trailing 12 month 1.172
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
P/E excluding extraordinary items, most recent fiscal year 21.68
P/E Normalized, most recent fiscal year 20.65
Price to sales - most recent fiscal year 6.03
Price to Tangible Book - most fiscal year 13.05
Price to Free Cash Flow per Share - most recent fiscal year 20.31
Price to Cash Flow per share - trailing 12 month 18.34
Price to Book - most recent fiscal year 5.70
P/E excluding extraordinary items high, trailing 12 months 25.89
P/E excluding extraordinary items low, trailing 12 months 16.46
Net Debt, LFI -400.16
Net Debt, LFY -643.32
Dividend Yield - 5 Year Average 0.86%
Dividend Yield - indicated annual dividend divided by closing price 1.04%
Current Dividend Yield - Common Stock Primary Issue, LTM 1.05%
Cash flow, liquidity and leverage measures, sourced from Morningstar.
Free Cash Flow - most recent fiscal year 1,702.90
LT debt/equity - most recent fiscal year 8.15%
Payout ratio - most recent fiscal year 23.01%
Total debt/total equity - most recent fiscal year 12.54%
LT debt/equity - most recent half-year 7.05%
Total debt/total equity - most recent half-year 10.27%
Free Cash Flow - trailing 12 month 1,702.01
Payout ratio - trailing 12 month 22.40%
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
Revenue - most recent fiscal year 5,653.44
Revenue - trailing 12 month 5,732.68
EBITD - most recent fiscal year 2,113.65
EBITD - trailing 12 month 2,192.59
Earnings before taxes - most recent fiscal year 1,919.42
Earnings before taxes - trailing 12 month 2,011.78
Net Income available to common - most recent fiscal year 1,523.29
Net Income available to common - trailing 12 months 1,593.17
Earnings before taxes Normalized - most recent fiscal year 2,041.16
Net Income Available to Common, Normalized - most recent fiscal year 1,631.85
Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM 1.15
Profitability margins for the most recent fiscal year, sourced from Morningstar.
Net Profit Margin % - 1st historical fiscal year 26.94%
Net Profit Margin % - trailing 12 month 27.79%
Operating margin - 1st historical fiscal year 33.76%
Operating margin - trailing 12 month 33.13%
Pretax margin - trailing 12 month 35.09%
Pretax margin - 1st historical fiscal year 33.95%
Operating Margin - 5 year average 30.27%
Pretax Margin - 5 year average 29.29%
Free Operating Cash Flow/Revenue, 5 Year Average 27.08%
Free Operating Cash Flow/Revenue, TTM 29.69%
Net Profit Margin - 5 year average 23.80%
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
Return on average assets - most recent fiscal year 17.82%
Return on average assets - trailing 12 month 18.62%
Return on average equity - most recent fiscal year 24.19%
Return on average equity - trailing 12 month 25.31%
Return on average assets - 5 year average 16.24%
Return on average equity - 5 year average 24.10%
Net Income/employee - most recent fiscal year 133,974.76
Revenue/employee - most recent fiscal year 497,224.54
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
Revenue growth rate, 5 year 12.08%
EPS growth rate, 5 year 26.34%
Growth rate% - dividend, 3 year 10.89%
Revenue/share (5 yr growth) 12.14%
Growth rate% - Revenue, 3 year 10.21%
Growth rate% - EPS, 3 year 19.64%
Book value per share growth rate, 5 year 18.17%
Capital Spending growth rate, 5 year 8.69%
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR 13.98%
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.

Financial forecast (USD, millions except per share)

Actuals Estimates
2026 202720282029
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.

Financials (USD, millions)

Period end: JUN 22JUN 23JUN 24JUN 25JUN 26
Fiscal year: 20222023202420252026
Period length: 12 months12 months12 months12 months12 months
Displays all company announcements released by the company to the exchange, sourced from Morningstar.

Announcements

DATE TIME HEADING PAGES

Opinion

Action

Business Summary

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

WATCH Pulse Check Webinar: Opportunities in the unloved parts of the market Recorded Wednesday 27st September
image description

Relevant suggested news and content from the site

image description
ASX 200
image description
Webinar Recording: Are commodities entering a Supercycle?
image description
Thursday 11th September – Dow off -220pts, SPI off -20pts
image description
Flag System – NXT – Source Market Matters
image description
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
image description
Wednesday 10th September – Dow up +196pts, SPI down -4pts
image description
Overview
image description
Buy Hold Sell: 5 ASX tech stocks bouncing back from the SaaS-pocalypse
image description
Applied Materials (AMAT US)
image description
Pulse Check Webinar: Portfolio positioning post the Budget
Back to top